Redcare Pharmacy NV (HAM:RDC) EBIT: €-23 Mil (TTM As of Mar. 2026)


HAM:RDC Redcare Pharmacy NV HAM:RDC
14 GF Score
Price €64.85
GF Value €179.32
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Redcare Pharmacy NV EBIT?

Redcare Pharmacy NV HAM:RDC -1.52% 14 EBIT is €-23 Mil as of Mar. 2026. GuruFocus rates HAM:RDC with a GF Score™ of 14/100 and a GF Value™ of €179.32 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Redcare Pharmacy NV's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-23 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Redcare Pharmacy NV's annualized ROC % for the quarter that ended in Mar. 2026 was -1.98%. Redcare Pharmacy NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -3.56%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Redcare Pharmacy NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1.43%.


Redcare Pharmacy NV  (HAM:RDC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Redcare Pharmacy NV's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-14.8 * ( 1 - 0% )/( (730.6 + 764.7)/ 2 )
=-14.8/747.65
=-1.98 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Redcare Pharmacy NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-10.4/( ( (190.7 + max(102.5, 0)) + (198.6 + max(92.2, 0)) )/ 2 )
=-10.4/( ( 293.2 + 290.8 )/ 2 )
=-10.4/292
=-3.56 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(129.5 + 214 + 72.7) - (280.5 + 0 + 33.2)
=102.5

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(156.4 + 214.8 + 73.1) - (278.7 + 0 + 73.4)
=92.2

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Redcare Pharmacy NV's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-22.8/1592.413
=-1.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Redcare Pharmacy NV EBIT Related Terms


Redcare Pharmacy NV EBIT Historical Data

* Premium members only.

The historical data trend for Redcare Pharmacy NV's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Redcare Pharmacy NV EBIT Chart

Redcare Pharmacy NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -69.32 -75.62 -6.35 -40.10 -27.80

Redcare Pharmacy NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.60 14.86 -0.80 -34.25 -2.60

Redcare Pharmacy NV EBIT Competitor Comparison

For the Pharmaceutical Retailers subindustry, Redcare Pharmacy NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redcare Pharmacy NV EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Redcare Pharmacy NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Redcare Pharmacy NV's EV-to-EBIT falls into.


HAM:RDC
14GF Score
Redcare Pharmacy NV HAM:RDC
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Redcare Pharmacy NV EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-23 Mil mean?
Redcare Pharmacy NV (HAM:RDC) has a EBIT of €-23 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Redcare Pharmacy NV.
Is Redcare Pharmacy NV's EBIT too high?
Redcare Pharmacy NV's current EBIT is €-23 Mil. Overall, Redcare Pharmacy NV has a GF Score™ of 14/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Redcare Pharmacy NV's EBIT compare to competitors?
Redcare Pharmacy NV's EBIT of €-23 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Redcare Pharmacy NV. Redcare Pharmacy NV's current EBIT is €-23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redcare Pharmacy NV stock overvalued right now?
Based on GuruFocus' analysis, Redcare Pharmacy NV (HAM:RDC) is currently considered Significantly Undervalued. The stock's GF Value™ is €179.32, compared to a current price of €64.85 — trading 63.8% below its estimated fair value. The current EBIT is €-23 Mil. Redcare Pharmacy NV's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Redcare Pharmacy NV (HAM:RDC), the current EBIT is €-23 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Redcare Pharmacy NV (HAM:RDC) Overvalued in 2026?

Based on GuruFocus' analysis, Redcare Pharmacy NV stock appears to be undervalued. The current stock price of €64.85 is trading 63.8% below its estimated GF Value™ of €179.32. GuruFocus considers Redcare Pharmacy NV to be Significantly Undervalued.

Key valuation signals for HAM:RDC:

  • EBIT: €-23 Mil
  • GF Value™: €179.32 vs. price of €64.85 (63.8% below fair value)
  • GF Score™: 14/100 with 2 warning signs

No single metric tells the full story. See the HAM:RDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Redcare Pharmacy NV Business Description

Address Erik de Rodeweg 11/13, Sevenum, ZH, NLD, 5975 WD
Redcare Pharmacy NV is an online pharmacy business for prescription and nonprescription (over-the-counter) pharmaceuticals, beauty and personal care products (BPC) and food supplements. Besides OTC, nutritional supplements, beauty and personal care products as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands. It operates in two segments, namely DACH segment that includes sales in Germany, Austria and Switzerland; and the International segment that includes sales across Belgium, the Netherlands, France and Italy. The DACH segment accounts for the majority of the revenue.
14GF Score

Get the complete analysis for HAM:RDC

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€64.85
Price
€179.32
GF Value